149 related articles for article (PubMed ID: 10213347)
1. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide.
Klepzig H; Kober G; Matter C; Luus H; Schneider H; Boedeker KH; Kiowski W; Amann FW; Gruber D; Harris S; Burger W
Eur Heart J; 1999 Mar; 20(6):439-46. PubMed ID: 10213347
[TBL] [Abstract][Full Text] [Related]
2. Effects of K(ATP) channel blockade by glibenclamide on the warm-up phenomenon.
Tomai F; Danesi A; Ghini AS; Crea F; Perino M; Gaspardone A; Ruggeri G; Chiariello L; Gioffrè PA
Eur Heart J; 1999 Feb; 20(3):196-202. PubMed ID: 10082152
[TBL] [Abstract][Full Text] [Related]
3. Impairment of myocardial protection in type 2 diabetic patients.
Lee TM; Chou TF
J Clin Endocrinol Metab; 2003 Feb; 88(2):531-7. PubMed ID: 12574175
[TBL] [Abstract][Full Text] [Related]
4. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker.
Tomai F; Crea F; Gaspardone A; Versaci F; De Paulis R; Penta de Peppo A; Chiariello L; Gioffrè PA
Circulation; 1994 Aug; 90(2):700-5. PubMed ID: 8044938
[TBL] [Abstract][Full Text] [Related]
5. Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits.
Nieszner E; Posa I; Kocsis E; Pogátsa G; Préda I; Koltai MZ
Exp Clin Endocrinol Diabetes; 2002 Aug; 110(5):212-8. PubMed ID: 12148084
[TBL] [Abstract][Full Text] [Related]
6. [Sulphonylurea derivatives and the cardiovascular system].
Filipiak KJ
Przegl Lek; 2000; 57 Suppl 4():19-22. PubMed ID: 11293225
[TBL] [Abstract][Full Text] [Related]
7. Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.
Abbink EJ; Pickkers P; Jansen van Rosendaal A; Lutterman JA; Tack CJ; Russel FG; Smits P
Diabet Med; 2002 Feb; 19(2):136-43. PubMed ID: 11874430
[TBL] [Abstract][Full Text] [Related]
8. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
Clark HE; Matthews DR
Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia.
Holstein A; Plaschke A; Hammer C; Egberts EH
Eur J Clin Pharmacol; 2003 Jun; 59(2):91-7. PubMed ID: 12698302
[TBL] [Abstract][Full Text] [Related]
10. Effects of glibenclamide, a K(ATP) channel blocker, on warm-up phenomenon in type II diabetic patients with chronic stable angina pectoris.
Ovünç K
Clin Cardiol; 2000 Jul; 23(7):535-9. PubMed ID: 10894443
[TBL] [Abstract][Full Text] [Related]
11. Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty.
Lee TM; Su SF; Chou TF; Lee YT; Tsai CH
Circulation; 2002 Jan; 105(3):334-40. PubMed ID: 11804989
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular effects of conventional sulfonylureas and glimepiride.
Geisen K; Végh A; Krause E; Papp JG
Horm Metab Res; 1996 Sep; 28(9):496-507. PubMed ID: 8911987
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy].
González-Ortiz M; Martínez-Abundis E;
Rev Invest Clin; 2004; 56(3):327-33. PubMed ID: 15612515
[TBL] [Abstract][Full Text] [Related]
14. Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance.
Charpentier G; Fleury F; Dubroca I; Vaur L; Clerson P
Diabetes Metab; 2005 Apr; 31(2):189-95. PubMed ID: 15959425
[TBL] [Abstract][Full Text] [Related]
15. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.
Massi-Benedetti M; Herz M; Pfeiffer C
Horm Metab Res; 1996 Sep; 28(9):451-5. PubMed ID: 8911982
[TBL] [Abstract][Full Text] [Related]
16. Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia.
Spallarossa P; Schiavo M; Rossettin P; Cordone S; Olivotti L; Cordera R; Brunelli C
Diabetes Care; 2001 Apr; 24(4):738-42. PubMed ID: 11315840
[TBL] [Abstract][Full Text] [Related]
17. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
[TBL] [Abstract][Full Text] [Related]
18. Glimepiride reduces mononuclear activation of the redox-sensitive transcription factor nuclear factor-kappa B.
Schiekofer S; Rudofsky G; Andrassy M; Schneider J; Chen J; Isermann B; Kanitz M; Elsenhans S; Heinle H; Balletshofer B; Häring HU; Schleicher E; Nawroth PP; Bierhaus A
Diabetes Obes Metab; 2003 Jul; 5(4):251-61. PubMed ID: 12795658
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.
González-Ortiz M; Guerrero-Romero JF; Violante-Ortiz R; Wacher-Rodarte N; Martínez-Abundis E; Aguilar-Salinas C; Islas-Andrade S; Arechavaleta-Granell R; González-Canudas J; Rodríguez-Morán M; Zavala-Suárez E; Ramos-Zavala MG; Metha R; Revilla-Monsalve C; Beltrán-Jaramillo TJ
J Diabetes Complications; 2009; 23(6):376-9. PubMed ID: 18849173
[TBL] [Abstract][Full Text] [Related]
20. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
Nissen SE; Nicholls SJ; Wolski K; Nesto R; Kupfer S; Perez A; Jure H; De Larochellière R; Staniloae CS; Mavromatis K; Saw J; Hu B; Lincoff AM; Tuzcu EM;
JAMA; 2008 Apr; 299(13):1561-73. PubMed ID: 18378631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
